# EDGAR Filing Document

**Accession Number:** 0001540013
**File Stem:** 0001104659-25-120884
**Filing Date:** 2025-12
**Character Count:** 20290
**Document Hash:** c54b724ab21496e0fa53d30e209547c0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-120884.hdr.sgml**: 20251215

**ACCESSION NUMBER**: 0001104659-25-120884

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251215

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251215

**DATE AS OF CHANGE**: 20251215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quipt Home Medical Corp.
- **CENTRAL INDEX KEY:** 0001540013
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40413
- **FILM NUMBER:** 251570056

**BUSINESS ADDRESS:**
- **STREET 1:** 1019 TOWN DRIVE
- **CITY:** WILDER
- **STATE:** KY
- **ZIP:** 41076
- **BUSINESS PHONE:** 859-878-2220

**MAIL ADDRESS:**
- **STREET 1:** 1019 TOWN DRIVE
- **CITY:** WILDER
- **STATE:** KY
- **ZIP:** 41076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Protech Home Medical Corp.
- **DATE OF NAME CHANGE:** 20200714

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Patient Home Monitoring Corp.
- **DATE OF NAME CHANGE:** 20120119

?xml version='1.0' encoding='ASCII'? Quipt Home Medical Corp._December 15, 2025

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**December 15, 2025**

**Date of Report (Date of earliest event reported)**

## Quipt Home Medical Corp.
**(Exact name of registrant as specified in its charter)**

**British Columbia, Canada**

**(State or other jurisdiction of incorporation)**

---

| | |
|:---|:---|
| **001-40413** | **N/A** |
| **(Commission File Number)** | **(IRS Employer Identification No.)** |

---

---

| | |
|:---|:---|
| **1019 Town Drive** |  |
| **Wilder, Kentucky** | **41076** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(859) 878-2220**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u> <u>&nbsp;&nbsp;&nbsp;&nbsp; </u> <u>Trading Symbol(s)</u> <u>&nbsp;&nbsp;&nbsp;&nbsp; </u> <u>Name of each exchange on which registered</u> <br> Common Shares, without Par Value QIPT The Nasdaq Capital Market <br> Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02. Results of Operations and Financial Condition.**

On December 15, 2025, Quipt Home Medical Corp. (the "Company") issued a press release regarding the Company's financial results for the year ended September 30, 2025. A copy of that press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing. The press release includes Non-GAAP financial measures as defined in Regulation G.

**Use of Non-GAAP Financial Information:**

The press release also includes the most directly comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), information reconciling the Non-GAAP financial measures to the GAAP financial measures and a discussion of the reasons why the Company's management believes that presentation of the Non-GAAP financial measures provides useful information to investors regarding the Company's financial condition and results of operations. The Non-GAAP financial measures presented therein should be considered in addition to, not as a substitute for, or superior to, financial measures calculated and presented in accordance with GAAP.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 99.1 | [Press Release by Quipt Home Medical Corp. dated December 15, 2025.](qipt-20251215xex99d1.htm) |
| 104 | Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101. |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **Quipt Home Medical Corp.** | **Quipt Home Medical Corp.** |
| Date: | December 15, 2025 | By: | /s/ Hardik Mehta |
|  |  |  | Hardik Mehta |
|  |  |  | Chief Financial Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**QUIPT HOME MEDICAL REPORTS FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS**

Cincinnati, Ohio – December 15, 2025 – Quipt Home Medical Corp. (the "**Company**") (NASDAQ: QIPT; TSX:QIPT), a U.S.-based home medical equipment provider focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2025 financial results and operational highlights. These results pertain to the three months and year ended September 30, 2025 and are reported in U.S. Dollars under GAAP.

**Financial Highlights:**

● Revenue for Q4 2025 was $68.3 million compared to $61.3 million for Q4 2024, representing an 11% increase. Sequential organic revenue growth from Q3 2025 was strong at 5%.

● Recurring Revenue <sup>1</sup> for Q4 2025 was strong at 80% of total revenue, driven by the growth in the Company's resupply platform.

● Adjusted EBITDA <sup>1</sup> for Q4 2025 was $14.9 million (21.8% as a percentage of revenues) compared to $13.4 million (21.9% as a percentage of revenues) for Q4 2024, representing an 11% increase.

● Net income (loss) for Q4 2025 was ($3.6) million, or ($0.08) per diluted share, compared to ($2.9) million, or ($0.07) per diluted share for Q4 2024.

● Revenue for fiscal year 2025 was $245.4 million compared to $245.9 million for fiscal year 2024, representing a slight decrease.

● Adjusted EBITDA <sup>1</sup> for fiscal year 2025 was $55.9 million (22.8% as a percentage of revenue), compared to Adjusted EBITDA for fiscal year 2024 of $57.7 million (23.5% as a percentage of revenue), representing a 3% decrease.

● Net income (loss) for fiscal year 2025 was ($10.7) million, or ($0.24) per diluted share, compared to ($6.8) million, or ($0.16) per diluted share for fiscal year 2024.

● Cash flow from operating activities was $37.7 million for the year ended September 30, 2025, compared to $35.4 million for the year ended September 30, 2024.

● The Company reported $12.9 million of cash on hand as of September 30, 2025, compared to $11.3 million as of June 30, 2025. Total credit availability of $12.7 million as of September 30, 2025, with $9.1 million available towards the revolving credit facility and $3.6 million available pursuant to the delayed-draw term loan facility.

● The Company maintains a conservative balance sheet with Net Debt to Adjusted EBITDA Leverage Ratio <sup>1</sup> of 1.8x.

**Operational Highlights:**

● The Company's customer base increased 10% year over year to 346,000 unique patients served in fiscal year 2025 compared to 314,000 unique patients in fiscal year 2024.

● Compared to 854,000 unique set-ups/deliveries in fiscal year 2024, the Company completed 917,000 unique set-ups/deliveries in fiscal year 2025, an increase of 7%. This includes 486,000 respiratory resupply set-ups/deliveries for the year ended September 30, 2025, compared to 480,000 for the year ended September 30, 2024, an increase of 1%, which the Company credits to its continued use of technology and centralized intake processes.

------

<sup>1</sup> Non-GAAP financial measure or ratio. See "Non-GAAP Financial Measures" below for additional information.

------

**Management Commentary:**

"Our fiscal 2025 performance underscores both the durability of our model and the accelerating momentum we generated through the back half of the year," said Gregory Crawford, Chairman and CEO of the Company. "In the fourth quarter, we delivered strong sequential organic growth, effectively managed industry-wide pressures, and continued scaling our platform. I want to thank the entire Quipt team for their unwavering commitment to operational excellence and for the exceptional support they provide to our patients and healthcare partners every single day."

"Our results highlight the strength of our core operations and the renewed momentum across the business," added Hardik Mehta, Chief Financial Officer. "As expected, we saw accelerating sequential organic growth throughout the back half of fiscal 2025, supported by improving referral activity and a stabilizing product mix across key categories. We anticipate consistent organic growth going forward, driven by our scalable operating platform, disciplined expense management, and the continued expansion of our diversified product offering."

The Company's audited financial statements, and related management's discussion and analysis, in the form of an *Annual Report on Form 10-K,* for the three months and year ended September 30, 2025, are available *at www.sec.gov,* under the Company's profile on SEDAR+ (www.sedarplus.com) and posted on the Company's web site at www.quipthomemedical.com.

**ABOUT QUIPT HOME MEDICAL CORP.**

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company's organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services, and making life easier for the patient.

***Forward-Looking Statements***

*Certain statements contained in this press release constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is ‎‎‎‎‎‎defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). The words "may", "would", "could", "should", "potential", ‎‎‎‎‎‎‎"will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect", "outlook", or the negatives thereof or variations of such words, and similar expressions ‎‎‎‎‎as ‎they relate to the Company. All statements ‎other ‎than ‎statements of ‎‎historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-‎looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the ‎Company's ‎current ‎views and ‎‎intentions with respect to future ‎events, and current information available to the ‎Company, and ‎are ‎subject to ‎‎certain risks, uncertainties and ‎assumptions. Many ‎factors could cause the actual ‎results, ‎‎performance or achievements that may be ‎expressed ‎or implied by such ‎forward-looking statements to ‎vary from ‎‎those described herein should one or more ‎of these ‎risks or ‎uncertainties materialize. Examples of such ‎risk ‎factors ‎include, without limitation: risks related ‎to credit, market ‎‎‎(including equity, commodity, foreign exchange ‎and interest ‎rate), ‎liquidity, operational ‎‎(including technology ‎and ‎infrastructure), reputational, insurance, ‎strategic, ‎regulatory, legal, ‎environmental, and ‎capital adequacy; the ‎‎general business and economic conditions in ‎the regions ‎in which the ‎Company operates; ‎the ability of the ‎‎Company to execute on key priorities, including the ‎successful ‎completion of ‎acquisitions, ‎business retention, and ‎‎strategic plans and to attract, develop and retain ‎key ‎executives; difficulty ‎integrating ‎newly acquired businesses; ‎‎the ability to implement business strategies and ‎‎pursue business opportunities; low ‎profit ‎market segments; ‎‎disruptions in or attacks (including cyber-attacks) on ‎‎the Company's information ‎technology, ‎internet, network ‎‎access or other voice or data communications systems or ‎‎services; the evolution of ‎various types ‎of fraud or other ‎‎criminal behavior to which the Company is exposed; the ‎‎failure of third parties to ‎comply with ‎their obligations to ‎‎the Company or its affiliates; the impact of new and ‎‎changes to, or application of, ‎current ‎laws and regulations; ‎‎decline of reimbursement rates; dependence on few ‎‎payors; possible new drug ‎discoveries; a ‎novel business ‎model; ‎dependence on key suppliers; granting of permits ‎‎and licenses in a highly ‎regulated ‎business; legal proceedings and litigation, including as it relates to the civil ‎‎investigative demand ("CID") ‎received from the Department of Justice; ‎increased competition; ‎changes in ‎foreign currency rates; ‎increased ‎‎funding costs and market volatility due to ‎market illiquidity and ‎competition for ‎funding; the ‎availability of funds ‎‎and resources to pursue operations; ‎critical accounting ‎estimates and changes ‎to accounting ‎standards, policies, ‎‎and methods used by the Company; the Company's status as an emerging growth company and a smaller reporting company; the occurrence of ‎natural and unnatural ‎catastrophic ‎events or health epidemics or concerns; as well as those risk factors ‎discussed or ‎‎referred to ‎in the Company's disclosure ‎documents filed with ‎United States Securities and Exchange ‎Commission ‎ and ‎available at www.sec.gov, including the Company's most recent Annual Report on Form 10-K, and with ‎the securities ‎regulatory authorities in certain provinces of ‎Canada and ‎‎‎available at www.sedarplus.com. Should any ‎factor affect ‎the Company in an unexpected manner, or ‎should ‎‎‎assumptions underlying the forward-looking ‎statement prove ‎incorrect, the actual results or events may ‎differ ‎‎‎materially from the results or events predicted. ‎Any such forward-‎looking statements are expressly qualified ‎in their ‎‎‎entirety by this cautionary statement. Moreover, ‎the Company ‎does not assume responsibility for the ‎accuracy or ‎‎‎completeness of such forward-looking* 

------

*‎statements. The ‎forward-looking statements included in this ‎press release are made as of the date of this press ‎release and the ‎Company undertakes no obligation to publicly ‎update or revise ‎‎‎any forward-looking statements, ‎other than as ‎required by applicable law‎.‎*

***Non-GAAP Financial Measures***

*This press release refers to "Adjusted EBITDA", "Recurring Revenue", and "Net Debt to Adjusted EBITDA Leverage Ratio", which are non-GAAP financial measures that do not have standardized meanings prescribed by generally accepted accounting principles in the United States ("GAAP"). The ‎Company's presentation of these financial measures may not be comparable to similarly titled measures used by ‎other companies. These financial measures are intended to provide additional information to investors concerning ‎the Company's performance.‎*

*Adjusted EBITDA is calculated as net loss, and adding back depreciation and amortization, right-of-use operating lease amortization and interest, interest expense, net, provision (benefit) for income taxes, certain professional fees, including those related to the CID, the loss of private issuer status, and proxy contests and other actions of activist shareholders, stock-based compensation, acquisition-related costs, change in fair value of derivative liability – interest rate swaps, gain on disposals of property and equipment, loss (gain) on foreign currency transactions, and share of loss in equity method investment. The following table shows our non-GAAP measure, Adjusted EBITDA, reconciled to our GAAP net loss for the ‎following indicated periods‎ (in $millions)‎:‎*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three**<br>**months ended**<br>**September**<br>**30, 2025** | **For the three**<br>**months ended**<br>**September**<br>**30, 2024** | **For the**<br>**year ended**<br>**September**<br>**30, 2025** | **For the**<br>**year ended**<br>**September**<br>**30, 2024** |
| Net loss | $(3.6) | $(2.9) | $(10.7) | $(6.8) |
| Add back: |  |  |  |  |
| Depreciation and amortization | 11.9 | 11.5 | 45.5 | 44.6 |
| Interest expense, net | 1.6 | 1.5 | 6.3 | 6.4 |
| Right-of-use operating lease amortization and interest | 1.7 | 1.4 | 6.4 | 6.0 |
| Provision (benefit) for income taxes | 0.1 | (0.4) | 0.2 | 0.1 |
| Professional fees | 1.3 | 1.1 | 4.3 | 3.3 |
| Stock-based compensation | 1.4 | 0.3 | 4.0 | 2.5 |
| Acquisition-related costs | 0.6 | 0.1 | 0.8 | 0.4 |
| Change in fair value of derivative liability - interest rate swap | - | 1.0 | (0.4) | 1.1 |
| Gain on disposals of property and equipment | (0.3) | (0.1) | (1.2) | (0.1) |
| Gain (loss) on foreign currency transactions | 0.1 | (0.2) | 0.4 | (0.1) |
| Share of loss in equity method investment | 0.1 | 0.1 | 0.3 | 0.3 |
| Adjusted EBITDA | $14.9 | $13.4 | $55.9 | $57.7 |

---

*Recurring Revenue for Q4 2025 is calculated as rentals of medical equipment of $28.0 million plus sales of respiratory resupplies of $26.7 million for a total of $54.7 million, divided by total revenues of $68.3 million, or 80%.*

*Net Debt to Adjusted EBITDA Leverage Ratio is calculated as Net Debt, divided by (Adjusted EBITDA for Q4 times four), and is reconciled as follows (in $millions):*

---

| | |
|:---|:---|
|  | *As of and for the<br>three months<br>ended September 30,<br>2025* |
| *Senior credit facility, principal* | $*87.6* |
| *Equipment loans* | *12.2* |
| *Lease liabilities* | *19.9* |
| *Cash* | *(12.9)* |
| *Net Debt* | $*106.8* |
| *Adjusted EBITDA for Q4 times four* | $*59.7* |
| *Net Debt to Adjusted EBITDA Leverage Ratio* | *1.8x* |

---

For further information please visit our website at www.Quipthomemedical.com, or contact:

Cole Stevens

VP of Corporate Development

------

Quipt Home Medical Corp.

859-300-6455

<u>cole.stevens@myquipt.com</u>

Gregory Crawford

Chief Executive Officer

Quipt Home Medical Corp.

859-300-6455

investorinfo@myquipt.com

------